News

Eris Lifesciences shares rise on Natco tie-up for Semaglutide launchNatco has received approval from the Central Drugs Standard Control Organisation to manufacture the generic version of Semaglutide, with the launch expected in March 2026.By Meghna Sen  February 24, 2026, 12:44:57 PM IST (Published)1 Min ReadShares of Eris Lifesciences Ltd. gained as much as 3% on Tuesday, February 24, after the company announced a partnership with Natco Pharma Ltd. to launch Semaglutide in India.

Natco has received approval from the Central Drugs Standard Control Organisation to manufacture the generic version of Semaglutide, with the launch expected in March 2026.

The collaboration marks Eris' entry into the GLP-1 segment, further strengthening its diabetes portfolio.

Semaglutide is widely used in the treatment of Type 2 diabetes and is part of the GLP-1 class of therapies, which are gaining traction globally amid a rising burden of metabolic disorders, including diabetes and obesity.

With India witnessing a sharp increase in lifestyle-related diseases, the therapy is seen as a major growth opportunity.

The partnership brings together Eris' established presence in the diabetes segment and strong relationships with endocrinologists and diabetologists, along with Natco's manufacturing capabilities.

The company said the GLP-1 opportunity could serve as a long-term value driver and expects rapid adoption, leveraging its specialist reach.

With this move, Eris positions itself in the fast-growing next-generation metabolic therapies space.Continue ReadingTagsEris Life shareEris Lifesciences